title: [A retrospective analysis of our paclitaxel-eluting stent (Genius TAXCOR I) implantations and follow-up results].
abstract: OBJECTIVE
  We evaluated our paclitaxel-eluting stent (Genius TAXCOR I) implantations and follow-up results in patients with coronary artery disease.
  
  
  METHODS
  The study included 101 patients (75 men, 26 women; mean age 60±10 years) who underwent elective paclitaxel-eluting stent deployment for de novo native coronary artery lesions. Sixteen patients received two stents. Lesion types were as follows: type A (23.9%), type B1 (29.1%), type B2 (32.5%), and type C (14.5%). Twelve lesions (10.3%) exhibited mild tortuosity, 32 (27.4%) had mild calcification, 12 had (10.3%) an angulation of more than 45 degrees, while eight (7.7%) had thrombus. Following stent implantation, the patients were examined at 1, 6, and 12 months, and annually thereafter. The mean follow-up period was 48.9±5.7 months (range 35 to 60 months).
  
  
  RESULTS
  Stent implantation was successful in all the patients. The mean diameter stenosis was 82.8±9.9%, the mean stent diameter was 3.1±0.6 mm, and the mean stent length was 16.0±5.2 mm. During the follow-up period, 46 patients (45.5%) required coronary angiography, of which eight (17.4%) received target vessel revascularization, and four (8.7%) received target lesion revascularization. One patient (1.0%) died from sudden cardiac death.
  
  
  CONCLUSIONS
  The clinical and angiographic follow-up results of this study involving relatively low- and intermediate-risk patients indicate that the use of the Genius TAXCOR I stents is effective and beneficial for the prevention of stent thrombosis and restenosis.
authors.affiliation: Department of Cardiology, Medicine Faculty of Hacettepe University, Ankara, Turkey.
authors.forename: Giray
authors.initials: G
authors.lastname: Kabakcı
authors.forename: Uğur
authors.initials: U
authors.lastname: Canpolat
authors.forename: Ahmet Hakan
authors.initials: AH
authors.lastname: Ateş
authors.forename: Hikmet
authors.initials: H
authors.lastname: Yorgun
authors.forename: Hamza
authors.initials: H
authors.lastname: Sunman
authors.forename: Ergün Barış
authors.initials: EB
authors.lastname: Kaya
authors.forename: Muhammed
authors.initials: M
authors.lastname: Dural
authors.forename: Kudret
authors.initials: K
authors.lastname: Aytemir
authors.forename: Lale
authors.initials: L
authors.lastname: Tokgözoğlu
authors.forename: Ali
authors.initials: A
authors.lastname: Oto
mesh_terms: D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage*; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D017239:Paclitaxel